5-Bromo-1-(3-bromo-1-propenyl)-2-fluorobenzene | 149946-66-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Bromo-1-(3-bromo-1-propenyl)-2-fluorobenzene
• 英文别名: 4-bromo-2-[(E)-3-bromoprop-1-enyl]-1-fluorobenzene
• CAS: 149946-66-7
• 化学式: C₉H₇Br₂F
• 分子量: 293.961
• InChiKey: KAFHOWMWYZWXSR-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5-溴-2-氟苯甲醛 在 三溴化磷 作用下， 生成 5-Bromo-1-(3-bromo-1-propenyl)-2-fluorobenzene
  参考文献：
  名称：

  手性布朗斯台德酸通过氧化脱氢偶联催化烯丙胺的对映体选择性羰基化

  摘要：

  在手性布朗斯台德酸催化剂的存在下，开发了一种通过烯丙基胺与亚磷酸酯的对映体C–H膦酰基对映体选择性合成手性α-氨基膦酸酯的新策略。该方案成功地将直接的C–H氧化与不对称的膦酰化反应相结合，并显示出高对映选择性。

  DOI：

  10.1021/acs.orglett.6b01514

文献信息

• 3,4-dihydro-4-oxo-3-(2-propenyl)-1-phthalazineacetic acids and
  申请人：Lipha, Lyonnaise Industrielle Pharmaceutique

  公开号：US05489592A1

  公开（公告）日：1996-02-06

  Novel 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetic acids and derivatives of formula (I) ##STR1## in which R.sub.1 R.sub.2 and R.sub.3 are the same or different and stand for H, a halogen or a linear or branched aliphatic, saturated or unsaturated radical, substituted or not by at least one halogen or R.sub.4 residue such as defined below, except when R.sub.4 is H; R.sub.4 and R.sub.5 are the same or different and stand for H, a linear or branched aliphatic radical, saturated or unsaturated, an aryl or heteroaryl radical, said radicals being substituted or not by at least one grouping such as fluorine, chlorine, bromine, methyl or trifluoromethyl, where R.sub.4 and R.sub.5 do not simultaneously denote H; R.sub.6 stands for hydroxy or alkoxy radical; R.sub.7 stands for H, a halogen, a linear or branched aliphatic saturated or unsaturated radical, an alkoxy radical, said radicals being substituted or not by analiphatic or halogenated radical, a nitro group, a substituted or unsubstituted amino group, S(O)n R.sub.8 or a cyano group; n is equal to 0,1 or 2; R.sub.8 is an aliphatic, linear or branched radical, an aryl or heteroaryl radical, an amino radical, said radicals being substituted or not by an aliphatic or halogenated radical. This invention also relates to the optional tautomeric forms of said acids and their pharmaceutically acceptable base addition salts. Also described is a process for preparing said compounds and the drugs containing same.

  新颖的3,4-二氢-4-氧基-3(丙-2-烯基)-1-邻苯二甲酸和式(I)的衍生物##STR1##其中R.sub.1、R.sub.2和R.sub.3相同或不同，代表H、卤素或线性或支链脂肪饱和或不饱和基团，该基团至少被一个卤素或R.sub.4残基取代，R.sub.4不为H时，除非R.sub.4为H；R.sub.4和R.sub.5相同或不同，代表H、线性或支链脂肪基团、饱和或不饱和基团、芳基或杂环芳基，这些基团至少被氟、氯、溴、甲基或三氟甲基等基团取代或不取代，其中R.sub.4和R.sub.5不同时代表H；R.sub.6代表羟基或烷氧基基团；R.sub.7代表H、卤素、线性或支链脂肪饱和或不饱和基团、烷氧基基团，该基团被脂肪基或卤素基团取代或不取代、硝基基团、取代或未取代的氨基基团、S(O)nR.sub.8或氰基团；n等于0、1或2；R.sub.8是线性或支链脂肪基团、芳基或杂环芳基、氨基基团，这些基团被脂肪基或卤素基团取代或不取代。本发明还涉及所述酸的可选互变异构体形式及其药学上可接受的碱盐。还描述了制备所述化合物和含有相同化合物的药物的方法。
• ACIDES 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIQUES ET DERIVES, LEURS PREPARATIONS ET MEDICAMENTS LES CONTENANT
  申请人：LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE

  公开号：EP0607344A1

  公开（公告）日：1994-07-27
• US5489592A
  申请人：——

  公开号：US5489592A

  公开（公告）日：1996-02-06
• [EN] 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME
  申请人：LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE

  公开号：WO1993007109A1

  公开（公告）日：1993-04-15

  (EN) Novel 3,4-dihydro-4-oxo-3-(prop-2-enyl)-1-phtalazineacetic acids and derivatives of formula (I) in which R1, R2 and R3 are the same or different and stand for H, a halogen or a linear or branched aliphatic, saturated or unsaturated radical, substituted or not by at least one halogen or R4 residue such as defined below, except when R4 is H; R4 and R5 are the same or different and stand for H, a linear or branched aliphatic radical, saturated or unsaturated, an aryl or heteroaryl radical, said radicals being substituted or not by at least one grouping such as fluorine, chlorine, bromine, methyl or trifluoromethyl, where R4 and R5 do not simultaneously denote H; R6 stands for a hydroxy or alkoxy radical; R7 stands for H, a halogen, a linear or branched aliphatic saturated or unsaturated radical, an alkoxy radical, said radicals being substituted or not by an aliphatic or halogenated radical, a nitro group, a substituted or unsubstituted amino group, S(O)n R8 or a cyano group; n is equal to 0, 1 or 2; R8 is an aliphatic, linear or branched radical, an aryl or heteroaryl radical, an amino radical, said radicals being substituted or not by an aliphatic or halogenated radical. The invention also relates to the optional tautomeric forms of said acids and their pharmaceutically acceptable base addition salts. Also described is a process for preparing said compounds and the drugs containing same.(FR) La présente invention concerne de nouveaux acides 3,4-dihydro-4-oxo-3-(prop-2-ényl)-1-phtalazineacétiques et dérivés de formule (I) dans laquelle: R1, R2 et R3 sont identiques ou différents et représentent H, un halogène ou un radical aliphatique linéaire ou ramifié, saturé ou non saturé et substitué ou non par au moins un halogène ou reste R4 tel que défini ci-dessous à l'exception de R4 est H; R4 et R5 sont identiques ou différents et représentent H, un radical aliphatique linéaire ou ramifié, saturé ou non saturé, un radical aryle ou hétéroaryle, lesdits radicaux étant substitués ou non par au moins un groupement tel que fluor, chlore, brome, méthyle ou trifluorométhyle, R4 et R5 n'étant pas simultanément H; R6 représente un radical hydroxy ou alcoxy; R7 représente H, un halogène, un radical aliphatique linéaire ou ramifié, saturé ou non saturé, un radical alcoxy, lesdits radicaux étant substitués ou non par un radical aliphatique ou halogéné, un groupe nitro, un groupe amino substitué ou non, S(O)n R8 ou un groupe cyano; n est 0, 1 ou 2; R8 est un radical aliphatique, linéaire ou ramifié, un radical aryle ou hétéroaryle, un radical amino, lesdits radicaux étant substitués ou non par un radical aliphatique ou halogéné, ainsi que leurs formes tautomères éventuelles et leurs sels d'addition de bases pharmaceutiquement acceptables. L'invention concerne aussi des procédés de préparation de ces composés ainsi que des médicaments les contenant.
• Chiral Brønsted Acid Catalyzed Enantioselective Phosphonylation of Allylamine via Oxidative Dehydrogenation Coupling
  作者：Ming-Xing Cheng、Ran-Song Ma、Qiang Yang、Shang-Dong Yang

  DOI：10.1021/acs.orglett.6b01514

  日期：2016.7.1

  A new strategy for the synthesis of chiral α-amino phosphonates by enantioselective C–H phosphonylation of allylamine with phosphite in the presence of a chiral Brønsted acid catalyst has been developed. This protocol successfully integrates direct C–H oxidation with asymmetric phosphonylation and exhibits high enantioselectivity.

  在手性布朗斯台德酸催化剂的存在下，开发了一种通过烯丙基胺与亚磷酸酯的对映体C–H膦酰基对映体选择性合成手性α-氨基膦酸酯的新策略。该方案成功地将直接的C–H氧化与不对称的膦酰化反应相结合，并显示出高对映选择性。